Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Frustaci, S.
Right arrow Articles by Monfardini, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frustaci, S.
Right arrow Articles by Monfardini, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:669-672, 1993
© 1993 European Society for Medical Oncology

research-article

Epirubicin and ifosfamide in advanced soft tissue sarcomas

S. Frustaci1,, S. Foladore1, A. Buonadonna1, A. De Paoli2, D. Crivellari1, A. Carbone3, R. Sorio1, S. Morassut4 and S. Monfardini1

1Division of Medical Oncology, Centro di Riferimento Oncologico Aviano, Italy
2Department of Radiation Therapy, Centro di Riferimento Oncologico Aviano, Italy
3Div. of Pathology, Centro di Riferimento Oncologico Aviano, Italy
4Radiology Service, Centro di Riferimento Oncologico Aviano, Italy

Correspondence to: Sergio Frustaci, M.D., Division of Medical Oncology, Centro di Riferimento Oncologjco, V. Pedemontana Occidentale, 33081 Aviano (PN), Italy

Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients.

Patients and methods: Treatment consisted of: epirubicin 75 mg/m2 i.v. day 1; IFO 1.8 g/m2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3–4 weeks for at least three cycles.

Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31% (95% confidence limits ± 13%). Among the 13 visceral sarcomas no response was seen for the leio-myosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5–34+) for complete responses and 9 (range 4–42+) for partial responses. The median survival for responders is 18 months (range 2–60+) and for non-responders 10 months (range 1–33) (p ± 0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.

chemotherapy, epirubicin, ifosfamide, metastatic soft tissue sarcomas


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
G. D. Demetri, S. P. Chawla, M. von Mehren, P. Ritch, L. H. Baker, J. Y. Blay, K. R. Hande, M. L. Keohan, B. L. Samuels, S. Schuetze, et al.
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
J. Clin. Oncol., September 1, 2009; 27(25): 4188 - 4196.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Lopez, P. Vici, L. Di Lauro, and S. Carpano
Increasing Single Epirubicin Doses in Advanced Soft Tissue Sarcomas
J. Clin. Oncol., March 1, 2002; 20(5): 1329 - 1334.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Frustaci, F. Gherlinzoni, A. De Paoli, M. Bonetti, A. Azzarelli, A. Comandone, P. Olmi, A. Buonadonna, G. Pignatti, E. Barbieri, et al.
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial
J. Clin. Oncol., March 1, 2001; 19(5): 1238 - 1247.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.